Who
Christopher Sarchi
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Replimune Group.
In numbers
- Trades disclosed
- 20
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $619K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 16 Nov 2023
- Last trade
- 1 Jun 2026
- Last filed
- 3 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jun 2026filed 3 Jun 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $111K12,000 at $9.24 | filing |
| 1 Jun 2026filed 3 Jun 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $111K12,000 at $9.24 | filing |
| 18 May 2026filed 20 May 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $44K8,626 at $5.08 | filing |
| 18 May 2026filed 20 May 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $44K8,626 at $5.08 | filing |
| 2 Apr 2026filed 6 Apr 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $52K6,500 at $8.01 | filing |
| 2 Apr 2026filed 6 Apr 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $52K6,500 at $8.01 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Apr 2026filed 7 Apr 2026 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 19 Dec 2025filed 19 Dec 2025 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 17 Nov 2025filed 19 Nov 2025 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $47K5,208 at $9.10 | filing |
| 20 May 2025filed 22 May 2025 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $30K3,749 at $8.05 | filing |
| 1 Apr 2025filed 3 Apr 2025 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,500 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 18 Nov 2024filed 20 Nov 2024 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $56K5,207 at $10.78 | filing |
| 16 May 2024filed 20 May 2024 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $14K2,218 at $6.47 | filing |
| 1 Apr 2024filed 3 Apr 2024 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,675 at $0.00 | filing |
| 1 Apr 2024filed 3 Apr 2024 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —22,225 at $0.00 | filing |
| 16 Nov 2023filed 17 Nov 2023 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $57K5,255 at $10.92 | filing |
News
No headline names them, or the companies they trade most, lately.